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Abstract
Background: There is no standard palliative chemotherapy regimen in biliary tract cancers (BTC).
Fluoropyrimidine or gemcitabine, with or without platinum, are most frequently used. We conducted this
study to clarify the efficacy of palliative chemotherapy in BTC.
Methods: Patients with unresectable BTC treated with palliative chemotherapy between Oct 2001 and
Aug 2006 at Seoul National University Hospital were reviewed retrospectively. Histologically confirmed
cases of intrahepatic cholangiocarcinoma, gallbladder cancer, extrahepatic bile duct cancer, and ampulla of
Vater carcinoma were enrolled. We analyzed the efficacy of regimens: gemcitabine (G) versus
fluoropyrimidine (F) and with or without platinum (P).
Results: A total of 243 patients were enrolled. 159 patients (65%) were male and the median age of the
patients was 60 years (range 26–81). Intrahepatic cholangiocarcinoma, gallbladder cancer, extrahepatic bile
duct cancer, and ampulla of Vater carcinoma were 92, 72, 58, and 21 cases, respectively. The median
progression free survival (PFS) was 4.3 months (95% CI, 3.7–4.9) and median overall survival (OS) was 8.7
months (95% CI, 7.4–10.0). Ninety-nine patients received G-based chemotherapy (94 GP, 5 G alone), and
144 patients received F-based chemotherapy (83 FP, 61 F alone). The response rate (RR), disease control
rate (DCR), PFS and OS of G-based chemotherapy versus F-based chemotherapy were 16.7% vs. 19.5% (P
= 0.591), 52.8% vs. 58.9% (P = 0.372), 4.0 months vs. 4.3 months (P = 0.816), and 7.8 months vs. 9.1 months
(P = 0.848), respectively. Sixty-six patients received F or G without P, and 177 patients received F or G
with P. The RR, DCR, PFS and OS of chemotherapy without P versus chemotherapy including P were 12.7%
vs. 20.6% (P = 0.169), 46.0% vs. 60.6% (P = 0.049), 3.3 months vs. 4.4 months (P = 0.887), and 10.6 months
vs. 8.1 months (P = 0.257), respectively.
Conclusion: In unresectable BTC, F-based and G-based chemotherapy showed similar efficacy in terms
of RR, DCR, PFS and OS. The benefit of adding P to F or G was not significant except for DCR. Further
prospective studies which define the efficacy of various chemotherapeutic regimens in BTC are warranted.
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Biliary tract cancers (BTC) are relatively rare tumors with
a poor prognosis. BTC account for less than 2% of all
malignancies in the West [1], but BTC are more common
in Korea and Japan accounting for approximately 4% of
malignancies [2]. BTC are classified by locations, as intra-
hepatic cholangiocarcinoma, extrahepatic bile duct can-
cer, gallbladder carcinoma and ampulla of Vater
carcinoma [3]. The only curative treatment is surgical
resection, but over 75% of patients are unresectable, typi-
cally due to advanced stage at diagnosis [4]. Patients with
unresectable BTC can be considered for palliative chemo-
therapy, which is reported to improve overall survival and
quality of life over best supportive care [5], but a standard
chemotherapy for BTC has not been established.
Most BTC studies contain only a small number of patients
because of the low incidence of BTC, and the most fre-
quently used and studied drug in BTC is 5-fluorouracil (5-
FU), which is used alone or in combination with other
agents and has a response rate of 0–30% [6-9]. Gemcitab-
ine (G) was introduced in the treatment of BTC and has
been reported to show a response rate of 10–30% [10-16].
G is being used alone or in combination with other
agents, such as platinum and fluoropyrimidine [10-16].
Platinum (P), especially, has been reported to have single
agent activity with a response rate of about 20% [17]. In
addition, regimens that contain newer fluoropyrimidines
(F), including capecitabine and S-1, have been reported to
have response rates of 20–40% [18-21].
F and G have been two major drugs in this way in the
treatment of unresectable BTC, but no superiority
between F-based and G-based chemotherapy has been
identified. The National Comprehensive Cancer Network
(NCCN) guideline recommends 5-FU-based or G as first-
line regimen in unresectable BTC. However, no studies
directly comparing G with F in single or combination reg-
imens have been undertaken. As the incidence of BTC in
Korea is relatively higher than in the West, we have access
to a relatively large BTC patient pool as a single institute.
We conducted this study to demonstrate the efficacy of
palliative chemotherapy in BTC and to find out the clue to
the preferred regimen in a large BTC population. We par-
ticularly analyzed the efficacy of regimens: G vs. F and
with P vs. without P.
Methods
Study Design
We retrospectively reviewed 258 consecutive patients with
unresectable BTC who were treated with palliative chem-
otherapy between Oct 2001 and Aug 2006 at Seoul
National University Hospital. Patients with adenocarcino-
mas arising from intrahepatic cholangiocarcinoma, gall-
bladder carcinoma, extrahepatic bile duct cancer, and
ampulla of Vater carcinoma, which were histologically
confirmed, were included.
Fluoropyrimidines used in this study included 5-FU, S-1,
capecitabine and uracil-tegafur (UFT). 5-FU monotherapy
consisted of 5-FU 375–500 mg/m2/day by bolus infusion
alone or modulated with levofolinic acid (leucovorin) 25
mg/m2/day from day 1 to 5 every 4 weeks (Mayo regi-
men). S-1 was used alone at a dose of 40 mg/m2 twice
daily for 28 days, followed by a 14-day rest period, and
capecitabine was used alone at a dose of 2500 mg/m2/day
for 14 days, followed by a 7-day day rest period. UFT was
used alone at a dose of 300 mg/m2/day for 28 days, fol-
lowed by a 7-day rest period. 5-FU combination with P
consisted of 5-FU administered intravenously at a dose of
1200 mg/m2/day over 10 hours from day 1 to 4 and cispl-
atin 60 mg/m2/day administered intravenously over 15
minutes on day 1 every 3 weeks. S-1 or capecitabine was
also administered with a same dosage and schedule of cis-
platin. Gemcitabine monotherapy consisted of gemcitab-
ine 1000 mg/m2/day over 30 minutes on day 1, 8, and 15
every 4 weeks. In addition, G combination with P con-
sisted of gemcitabine administered intravenously at a
dose of 1200 mg/m2/day over 30 minutes on day 1 and 8
and cisplatin administered intravenously at a dose of 60
mg/m2/day over 15 minutes on day 1 every 3 weeks. Plat-
inum compounds included cisplatin, and oxaliplatin.
When oxaliplatin was used instead of cisplatin, it was used
at a dose of 130 mg/m2/day over 2 hours with S-1 or
capecitabine on day 1 every 3 weeks or 100 mg/m2/day
over 2 hours with gemcitabine on day 1 every 2 weeks.
We excluded 14 patients who received both G and F
simultaneously as first-line chemotherapy and one
patient who received a regimen other than G or F (paclit-
axel and cisplatin) because they were inconsistent with
the aim of this study. In total, 243 patients were enrolled
finally in this study. We assessed response to chemother-
apy in each patient according to the RECIST (Response
Evaluation Criteria in Solid Tumors) [22]. Appropriate
imaging studies, including CT scans, were usually per-
formed every two cycles. The proportions of patients in
whom biliary drainage procedures, such as biliary stent
and percutaneous transhepatic biliary drainage (PTBD),
were performed were evaluated, and the infections which
frequently occurred to patients with BTC, such as cholan-
gitis and liver abscess, were defined as disease-associated
infections. Our study was approved by the institutional
review board of the Seoul National University Hospital,
Seoul, Korea.
Statistical Analysis
We analyzed the efficacy of first-line chemotherapy. Spe-
cifically, we compared the efficacy of G-based vs. F-based
regimens, and with or without P. The median overall sur-Page 2 of 9
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were measured. OS was calculated from the first day of
palliative chemotherapy to the day of death or last fol-
lowed-up. PFS was calculated from the first day of pallia-
tive chemotherapy to the day of progression or last
followed-up. Descriptive statistics were reported as medi-
ans and proportions, and χ2 test was used to compare
baseline characteristics between chemotherapy groups.
Confidence intervals (95% CI) for response rate and dis-
ease control rate were estimated by binomial distribution
[23]. Survival curves were estimated by the Kaplan-Meier
method for OS and PFS, and 95% CI for the median time
to event was calculated by Greenwood's formula [23]. The
log-rank test was used to compare the distribution of sur-
vival between groups. Statistical analyses were performed
by the statistical software package SPSS version 12.0 K




We finally enrolled 243 patients with unresectable BTC
(Table 1). There were 159 (65%) males and 84 (35%)
females. The median age of the patients was 60 years
(range 26–81 years). The median follow-up duration was
6.5 months (range 0.0–47.8 months). ECOG perform-
ance status (PS) at baseline was either 0 or 1 in 215
patients (88%). There were 36 patients (15%) who under-
went palliative surgery. Intrahepatic cholangiocarcinoma,
gallbladder carcinoma, extrahepatic bile duct cancer, and
ampulla of Vater carcinoma were 92 (38%), 72 (30%), 58
(24%), and 21 (9%) cases, respectively. Sixty-four patients
(26%) had biliary stents or bypasses for obstructive dis-
ease during treatment. Disease-associated infections were
detected in 62 patients (26%).
In a total, 144 patients (59%) received F-based chemo-
therapy. They took oral F such as capecitabine, S1, and
UFT besides intravenous 5-FU. The proportions of the
patients who took 5-FU, S1, capecitabine, and UFT were
44%, 39%, 15% and 2%, respectively. The proportions of
the patients who were treated in combination with P
among these patients were 27%, 89%, 73% and 0%,
respectively (Table 2). Ninety-nine patients (41%)
received G-based chemotherapy. Most (95%) of them
were treated in combination with P. One hundred and
seventy-seven (73%) patients received chemotherapy
combined with P. Most of the patients received cisplatin,
and only 9 patients (5%) received oxaliplatin.
The median age, sexual distribution, baseline PS, and the
distribution of disease types were not significantly differ-
ent between F-based and G-based chemotherapy groups
(Table 3). There was a significant difference in biliary
stents or bypasses between the groups (P = 0.040), but no
significant difference in disease-associated infections,
which are considered to develop easily under these condi-
tions.
When the patients were divided according to the presence
of platinum compounds, age and baseline PS in the two
groups were significantly different (Table 4). Other char-
acteristics showed no difference between groups. In our
study, elderly patients tended to be treated with oral
chemotherapeutic agents, such as S-1, capecitabine and
UFT, which all belonged to non-platinum group. This fact
seems to contribute to more increased median age in non-
Table 1: Patient characteristics
Characteristics No. of patients %
Total Number 243




ECOG performance status at baseline
0 – 1 215 88
2 28 12
Disease
Intrahepatic cholangiocarcinoma 92 38
Gallbladder cancer 72 30
Extrahepatic bile duct cancer 58 24
Ampulla of Vater carcinoma 21 9
Recurrent 84 35
Initially metastatic 154 63
Biliary stent or bypass during treatment 64 26
Disease-associated infection during treatment (cholangitis, liver abscess) 62 26
ECOG, Eastern Cooperative Oncology GroupPage 3 of 9
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therapeutic agents were significantly older than those
treated with intravenous chemotherapeutic agents (65
years vs. 59 years, P = 0.025).
Treatment Outcomes
The overall response rate (RR) of first-line chemotherapy
was 18.3% (95% CI, 13.2–23.5%) and the disease control
rate (DCR) was 56.4% (95% CI, 49.8–63.0%). The
median duration of first-line chemotherapy was 2.1
months (range, 0.0–13.2 months), and median duration
of response was 4.5 months (range, 1.1–13.1 months).
The median OS was 8.7 months (95% CI, 7.4–10.0
months) and median PFS was 4.3 months (95% CI, 3.7–
4.9 months).
Treatment outcomes including survival time were also
analyzed according to disease types. The median OS was
7.6 months (95% CI, 6.0–9.1 months) for intrahepatic
cholangiocarcinoma, 8.8 months (95% CI, 6.4–11.1
months) for gallbladder carcinoma, 9.4 months (95% CI,
6.0–12.7 months) for extrahepatic bile duct cancer, and
11.7 months (95% CI, 8.2–15.3 months) for ampulla of
Vater carcinoma. The median PFS was 4.3 months (95%
CI, 3.3–5.3 months) for intrahepatic cholangiocarci-
noma, 4.3 months (95% CI, 3.3 – 5.3 months) for gall-
bladder carcinoma, 4.4 months (95% CI, 2.7–6.1
months) for extrahepatic bile duct cancer, and 2.9 months
(95% CI, 1.4–4.4 months) for ampulla of Vater carci-
noma. There was no statistically significant difference in
either OS or PFS among disease types. RR and DCR also
showed no statistically significant differences among dis-
ease types. These results were the same in subgroup anal-
ysis of gallbladder carcinoma vs. all other BTC.
Gallbladder carcinoma showed similar efficacy to all
other BTC in all aspects of RR, DCR, OS, and PFS (RR
20.6% vs. 16.8%, P = 0.494; DCR 63.5% vs. 53.3%, P =
0.165; OS 8.8 months (95% CI, 6.7–10.8 months) vs. 8.1
months (95% CI, 7.0–9.2 months), P = 0.370; PFS 4.3
months (95% CI, 3.4–5.2 months) vs. 4.0 months (95%
CI, 3.3–4.7 months), P = 0.515). When disease types were
classified into two groups, i.e. intrahepatic and extrahe-
patic bile duct cancers, the extrahepatic bile duct cancer
group had significantly longer median OS than the intra-
hepatic bile duct cancer group (9.9 months vs. 7.6
months, P = 0.025).
Table 2: Number of patients according to the regimens
Type of Regimens With P Without P Total
N (%) N (%) N (%)
F-based regimens 83 (58) 61 (42) 144 (100)
5-FU 17 46 63
S1 50 6 56
Capecitabine 16 6 22
UFT 0 3 3
G-based regimens 94 (95) 5 (5) 99 (100)
Total 177 (73) 66 (27) 243 (100)
P, platinum; F, fluoropyrimidines; 5-FU, 5-fluorouracil; UFT, uracil-
tegafur; G, gemcitabine
Table 3: Comparison of F-based group vs. G-based group
Characteristics F Group (%) G Group (%) P value
Total Number 144 99
Median age, years (range) 60 (range 29–80) 61 (range 26–81)
Sex 0.831
Male 95 (66.0) 64 (64.6)
Female 49 (34.0) 35 (35.4)
ECOG performance status at baseline 0.06
0 – 1 132 (91.7) 83 (83.8)
≥ 2 12 (8.3) 16 (16.2)
Disease 0.966
Intrahepatic cholangiocarcinoma 54 (37.5) 38 (38.4)
Gallbladder cancer 42 (29.2) 30 (30.3)
Extrahepatic bile duct cancer 36 (25.0) 22 (22.2)
Ampulla of Vater carcinoma 12 (8.3) 9 (9.1)
Relapsed disease 51 (35.4) 33 (33.3) 0.737
Biliary stent or bypass during treatment 31 (21.5) 33 (33.3) 0.04
Disease associated infection during treatment (cholangitis, liver abscess) 31 (21.5) 31 (31.3) 0.086
Duration from off chemotherapy to death 3.5 months (95% CI, 2.9–4.0) 3.3 months (95% CI, 2.2–4.3) 0.752
ECOG, Eastern Cooperative Oncology Group; F, fluoropyrimidines; G, gemcitabine; CI, confidence intervalPage 4 of 9
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Ninety-nine patients received G-based chemotherapy
with or without P (94 GP, 5 G alone) as first-line chemo-
therapy, while 144 patients received F-based chemother-
apy with or without P as first-line chemotherapy (83 FP,
61 F alone) (Table 5). The RR and DCR of G-based vs. F-
based chemotherapy were 16.7% vs. 19.5% (P = 0.591)
and 52.8% vs. 58.9% (P = 0.372), respectively. The
median PFS and OS of G-based vs. F-based chemotherapy
were 4.0 months vs. 4.3 months (P = 0.816), and 7.8
months vs. 9.1 months (P = 0.848), respectively (Figure
1). F-based regimens showed better RR and DCR than G-
based regimens, but showed no statistically significant dif-
ference. Similarly, the median PFS and OS were better in
F-based regimens, but not significantly different.
Platinum-containing regimen vs. platinum non-containing regimen
Sixty-six patients received G or F without P, and 177
patients received G or F with P (Table 6). The RR and DCR
of chemotherapy without P vs. chemotherapy including P
were 12.7% vs. 20.6% (P = 0.169) and 46.0% vs. 60.6% (P
= 0.049), respectively. The median PFS and OS of chemo-
therapy without P vs. chemotherapy including P were 3.3
months vs. 4.4 months (P = 0.887), and 10.6 months vs.
8.1 months (P = 0.257) (Figure 2), respectively. The addi-
tion of P to G-based or F-based regimens caused statisti-
cally significant increase in DCR, but the benefit of adding
P was minimal in the RR, OS, and PFS. These results were
the same in a subgroup of patients less than 65 years. The
RR, DCR, PFS, and OS of chemotherapy without P vs.
chemotherapy including P in the subgroup less than 65
years were 12.1% vs. 21.7% (P = 0.225), 33.3% vs. 61.9%
(P = 0.004), 2.4 vs. 4.4 months (P = 0.387), and 9.0 vs. 9.6
months, (P = 0.540), respectively.
Gemcitabine with platinum vs. fluoropyrimidine with platinum
Ninety-four patients received G with P, and 83 patients
received F with P (Table 7). The RR, DCR, PFS, and OS of
GP vs. FP were 17.6% vs. 24.3%, (P = 0.310), 54.8% vs.
Table 4: Comparison of platinum group vs. non – platinum group
Characteristics Platinum Group (%) Non-Platinum Group (%) P value
Total Number 177 66
Median age, years (range) 58 (range 26–81) 64 (range 29–80) 0.003
Sex 0.247
Male 112 (63.3) 47 (71.2)
Female 65 (36.7) 19 (28.8)
ECOG performance status at baseline 0.047
0 – 1 161 (91.0) 54 (81.8)
≥ 2 16 (9.0) 12 (18.2)
Disease 0.361
Intrahepatic cholangiocarcinoma 72 (40.7) 20 (30.3)
Gallbladder cancer 51 (28.8) 20 (30.3)
Extrahepatic bile duct cancer 38 (21.5) 22 (22.2)
Ampulla of Vater carcinoma 16 (9.0) 5 (7.6)
Relapsed disease 62 (35.0) 22 (33.3) 0.805
Biliary stent or bypass during treatment 46 (26.0) 18 (27.3) 0.84
Disease associated infection during treatment (cholangitis, liver abscess) 43 (24.3) 19 (28.8) 0.475
Duration from off chemotherapy to death 3.3 months (95% CI, 2.6–3.9) 4.0 months (95% CI, 2.6–5.5) 0.071
ECOG, Eastern Cooperative Oncology Group; CI, confidence interval
Overall survival of F-based vs. G-based chemotherapy esti-mated by the Kaplan-Meier method; F: fluoropyrimidin s; G: gemcitabineFigure 1
Overall survival of F-based vs. G-based chemotherapy 
estimated by the Kaplan-Meier method; F: fluoropy-
rimidines; G: gemcitabine.Page 5 of 9
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0.787), and 8.0 months vs. 8.1 months, (P = 0.357),
respectively. Patients in G-based group (94 GP, 5 G alone)
more frequently received combination chemotherapy
with P compared with those in F-based group (83 FP, 61
F alone) (P < 0.0001), but the efficacy of GP was not sig-
nificantly different from that of FP in all aspects.
Post-progression treatment
In a total of 243 patients, 129 (53%) received second-line
chemotherapy after progression in first-line chemother-
apy. Among 144 F-pretreated patients, 76 received sec-
ond-line F-based or G-based chemotherapy, while 41
among 99 G-pretreated patients received second-line F-
based chemotherapy. In F-pretreated group, there were 52
in G-based chemotherapy group and 24 in F-reused
group. On the other hand, no patients in G-pretreated
group reused G-based chemotherapy.
Discussion
There is no defined standard palliative chemotherapy reg-
imen for unresectable BTC. The goal of our study was to
demonstrate the impact of palliative chemotherapy and to
compare the efficacy of the most frequently used agents in
BTC. Our results indicate that F-based regimens have a
trend to better RR and DCR, and longer median PFS and
OS than G-based regimens, but the difference failed to
show statistical significance. The efficacy of F-based regi-
mens, alone or in combination with other drugs, was ana-
lyzed, and the RR and DCR of F-based regimens were
19.5% and 58.9%, respectively. These results were compa-
rable to those reported in other studies [9]. Ducreux et al.
showed that a combination regimen of 5-FU, folinic acid
and cisplatin had a 19% RR and a 44% DCR. The median
PFS of 3.3 months and OS of 8.0 months in their study
were similar to the results in our study, 4.3 months and
9.1 months. Oral F, such as capecitabine, S-1 and UFT,
have also been evaluated in BTC. These agents, alone or in
combination with cisplatin, doxorubicin, and epirubicin,
showed significant antitumor activity [18-21,24]. In the
present study, 56% of patients who received F-based
chemotherapy used these oral agents.
Our study reports the efficacy of G-based regimens, alone
or in combination with other agents. The RR, DCR, PFS,
and OS of G-based regimens, alone or in combination
with other agents were 16.7%, 52.8%, 4.0 months and 7.8
months. Previously, G alone in various dosages and
schedules or in combination with P, F, or other agents
have shown considerable efficacy up to 60% of RR, 90%
or more of DCR, and from 5.0 to 16.0 months of the
median OS in BTC [11,25-27]. G-based chemotherapy in
our study showed a relatively low efficacy compared with
the efficacy reported in some previous studies [25-27].
One of possible explanation for this difference is that
patients treated with G-based regimens in our study had a
Table 5: Treatment outcomes of fluoropyrimidines vs. gemcitabine
F based G based P value
Number of patients 144 99 < 0.0001
With P 83 94
Without P 61 5
RR (%) 19.5 16.7 0.591
DCR (%) 58.9 52.8 0.372
PFS (months) 4.3 (95% CI, 3.3–5.3) 4.0 (95% CI, 2.9–5.1) 0.816
OS (months) 9.1 (95% CI, 7.1–11.1) 7.8 (95% CI, 6.5–9.2) 0.848
F, fluoropyrimidines; G, gemcitabine; P, platinum; RR, response rate; DCR, disease control rate; PFS, progression free survival; CI, confidence 
interval; OS, overall survival
Overall survival of chemotherapy with P vs. chemotherapy without P estimated by the Kaplan-Meier method; P: pl ti-numFigure 2
Overall survival of chemotherapy with P vs. chemo-
therapy without P estimated by the Kaplan-Meier 
method; P: platinum.Page 6 of 9
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cially prospective studies [28,29]. Moreover, the G-based
group showed a trend for a worse PS compared with the
F-based group (P = 0.06). It looks unavoidable due to the
retrospective nature of the present study. In one phase II
study and another retrospective study which reported the
effect of G-based chemotherapy, only 0% and 5% of
patients had ECOG PS ≥ 2, while 16% of patients in this
study had ECOG PS ≥ 2 [29,30].
Although F and G are two active chemotherapeutic agents
in BTC, a large population-based randomized study
which directly compares F-based regimens with G-based
regimens has not been performed. Our results, through
direct comparison of F-based with G-based regimens, sug-
gest similar efficacy in terms of RR, DCR, median PFS, and
OS in both chemotherapeutic agents.
Platinum compounds, such as cisplatin and oxaliplatin,
have been tested in single or combination regimens in
BTC. Cisplatin monotherapy has shown mostly unsatis-
factory activity [31], while oxaliplatin was reported to
have single-agent activity in BTC [17]. Furthermore, P was
reported to have synergistic effects with G or F in preclin-
ical studies [32,33], but the benefit on addition of P to G
or F has not been clarified due to a lack of large-scaled
phase III trials. Our study showed a possible benefit on
the addition of P to G or F, even if it had a minimal benefit
only in terms of disease control. As our non-P group was
older and had a poorer PS than our P group, we also ana-
lyzed the efficacy for patients less than 65 years. This sub-
group analysis only showed a minimal benefit in terms of
disease control as in total patients.
In our study, 83 (52%) of 144 patients who received F-
based chemotherapy received FP, while 94 (95%) of 99
patients who received G-based chemotherapy received GP
(P < 0.0001). Thus comparison of F-based with G-based
chemotherapy in fact means comparison of F-based with
GP in the present study. However, FP and GP showed sim-
ilar efficacy in subgroup analysis performed for more
detailed explanation.
Recently, a pooled analysis of clinical trials including 104
trials was conducted [34]. A total of 2810 patients with
BTC were analyzed. Subgroup analysis showed a signifi-
cantly higher RR for gallbladder carcinoma (GBC) com-
pared with cholangiocarcinoma (CC), but longer OS for
cholangiocarcinoma, and GP was suggested as the most
active regimen in BTC. Another subgroup analysis in this
pooled analysis compared patients treated with regimens
containing a specific drug (F, G, and P, etc.) with patients
treated with regimens not containing this drug. Treatment
with G and P-containing regimens demonstrated consist-
ently higher RR and DCR compared with G-free as well as
P-free regimens. In contrast, our study didn't show a dif-
ference of treatment efficacy between GBC and non-GBC
in BTC, and also the efficacy of GP was similar to that of
FP. As comparison of F vs. F-free regimens means F vs. G in
our study, it's not feasible to perform subgroup analysis
like that of the previous study. In a recent retrospective
study of survival benefits of palliative chemotherapy for
unresectable BTC, 179 patients treated with palliative
Table 6: Treatment outcomes of with platinum vs. without platinum
With Platinum Without Platinum P value
Number of patients 177 66
RR (%) 20.6 12.7 0.169
DCR (%) 60.6 46.0 0.049
PFS (months) 4.4 (95% CI, 3.7–5.1) 3.3 (95% CI, 2.3–4.3) 0.887
OS (months) 8.1 (95% CI, 7.0–9.3) 10.6 (95% CI, 7.9–13.2) 0.257
RR, response rate; DCR, disease control rate; PFS, progression free survival; CI, confidence interval; OS, overall survival
Table 7: Treatment outcomes of FP vs. GP
FP GP P value
Number of patients 83 94
RR (%) 24.3 17.6 0.310
DCR (%) 67.6 54.8 0.103
PFS (months) 4.6 (95% CI, 3.5–5.7) 4.3 (95% CI, 3.6–5.0) 0.787
OS (months) 8.1 (95% CI, 7.0–9.3) 8.0 (95% CI, 6.0–10.0) 0.357
F, fluoropyrimidines; P, platinum; G, gemcitabine; RR, response rate; DCR, disease control rate; PFS, progression free survival; CI, confidence 
interval; OS, overall survivalPage 7 of 9
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with the best supportive care (BSC) [30]. This study
showed that the chemotherapy group had a longer sur-
vival time than the BSC group. In addition, G was more
effective than 5-FU-based or cisplatin-based regimens,
with a reduction in mortality of about 50%. Those results
are contrary to our results, which suggest that G-based and
F-based regimens have similar efficacy. However, it is hard
to compare directly the efficacy of regimens because the
classifications of chemotherapy regimens in both studies
were different.
Studies on newer targeted agents, such as erlotinib and
cetuximab, are increasing in BTC, as in other malignancies
[35,36]. However, because the efficacy of these drugs is
still investigational, F-based or G-based chemotherapy
may be backbone of palliative chemotherapy in unresect-
able BTC for some time.
Our study has several limitations. Most of all, although
baseline characteristics of patients were statistically simi-
lar between chemotherapy groups, our study is a nonran-
domized and retrospective study. Consequently,
unexpected bias may exist. In addition, F used in this
study included various agents such as 5-FU, UFT, capecit-
abine, and S-1. Thus, the efficacy of each drug in F can be
different from that of total F-based chemotherapy in this
study. If we analyze independently each drug in F, how-
ever, it will not be easy to interpret exactly the results due
to a small number of patients who received each agent.
The efficacy of F-based vs. G-based chemotherapy may
seem to be similar because the number of patients
included in each group was not enough to show the dif-
ference. Moreover, we excluded patients who received F
and G at the same time or didn't receive F or G at all
because they were inconsistent with the objective of this
study. Even though a small number of patients were
excluded, it will also contribute potentially to selection
bias in our study.
However, our study has significance in spite of these sev-
eral limitations. BTC are rare tumors, but our study is a rel-
atively large population-based study due to higher
incidence of BTC in Korea. Moreover, the patients in this
study received similar supportive care in a single center
during chemotherapy. Further randomized controlled tri-
als are needed in BTC.
Conclusion
In conclusion, our results suggest that F-based and G-
based chemotherapy show similar efficacy in terms of RR,
DCR, PFS, and OS in BTC. In addition, the beneficial
effect of adding platinum to G or F was not significant
except in terms of DCR. Further prospective studies to
define the efficacy of various chemotherapeutic regimens
in BTC are warranted.
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